

3 July 2025

## Treatment of Breast Cancer

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?**

| Name of medicine                          | Number patients treated |
|-------------------------------------------|-------------------------|
| 1.1 Abemaciclib (Verzenios)               | 65                      |
| 1.2 Alpelisib (Piqray)                    | <5                      |
| 1.3 Elacestrant (Orserdu)                 | <5                      |
| 1.4 Fulvestrant (fulvestrant or Faslodex) | 42                      |
| 1.5 Inavolisib (Inaqovi)                  | <5                      |
| 1.6 Palbociclib (Ibrance)                 | 70                      |
| 1.7 Ribociclib (Kisqali)                  | 40                      |
| 1.8 Capivasertib (Truqap)                 | <5                      |
| 1.9 Talazoparib (Talzenna)                | <5                      |
| 1.10 Olaparib (Lynparza)                  | 26                      |

**Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?**

Figures for all breast cancer – ‘early’ detail not available.

| Name of combination or monotherapy | Number patients treated |
|------------------------------------|-------------------------|
| 2.1 Abemaciclib (Verzenios)        | 65                      |
| 2.2 Ribociclib (Kisqali)           | 40                      |
| 2.3 Olaparib (Lynparza)            | <5                      |

**Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period for which data are available?**

**3 July 2025**

Figures for all breast cancer – ‘curative’ detail not available.

| Name of combination or monotherapy | Number patients treated |
|------------------------------------|-------------------------|
| 3.1 Abemaciclib (Verzenios)        | 65                      |
| 3.2 Ribociclib (Kisqali)           | 40                      |

**Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of Jan 2025 and the end of Mar 2025, or latest 3-month period available?**

| Name of combination or monotherapy                                  | Number patients treated |
|---------------------------------------------------------------------|-------------------------|
| 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) | 7                       |
| 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)   | 9                       |
| 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)    | <5                      |

**Q5. How many patients were treated with Olaparib (Lynparza) for the following types of breast cancer in the 3 months between the start of Jan 2025 and the end of Mar 2025?**

| Type of breast cancer                            | Number patients treated |
|--------------------------------------------------|-------------------------|
| 5.1 All types of breast cancer                   | <5                      |
| 5.2 Locally advanced or metastatic breast cancer | <5                      |

**Q6. How many patients were treated in total with the following products in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?**

| Name of medicine                                                                            | Number patients treated |
|---------------------------------------------------------------------------------------------|-------------------------|
| 6.1 Pertuzumab (Perjeta)                                                                    | <5                      |
| 6.2 Pertuzumab with Trastuzumab (Phesgo)                                                    | 40                      |
| 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | 47                      |
| 6.4 Trastuzumab Deruxtecan (EnHertu)                                                        | 13                      |
| 6.5 Trastuzumab Emtansine (Kadcyla)                                                         | 19                      |
| 6.6 Tucatinib (Tukysa)                                                                      | 7                       |
| 6.7 Neratinib (Nerlynx)                                                                     | <5                      |

3 July 2025

**Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (*ICD-10 codes = C50\*, D509*) in the 3 months between 1st Jan 2025 to the end of Mar 2025, or latest 3-months for which data are available?**

| Name of medicine                                                                            | Number patients treated |
|---------------------------------------------------------------------------------------------|-------------------------|
| 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | 37                      |
| 7.2 Trastuzumab Deruxtecan (EnHertu)                                                        | 13                      |

**Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?**

Treatment intent detail not available.

| Treatment intent                                                                            | Number patients treated |
|---------------------------------------------------------------------------------------------|-------------------------|
| 8.1 Pertuzumab (Perjeta)                                                                    | <5                      |
| 8.2 Pertuzumab with Trastuzumab (Phesgo)                                                    | Not available           |
| 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) | Not available           |
| 8.4 Trastuzumab Emtansine (Kadcyla)                                                         | Not available           |

**Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?**

Neoadjuvant/adjuvant detail not available.

| Treatment intent                                                                            | Number patients treated |
|---------------------------------------------------------------------------------------------|-------------------------|
| 9.1 Pertuzumab (Perjeta)                                                                    | Not available           |
| 9.2 Pertuzumab with Trastuzumab (Phesgo)                                                    | Not available           |
| 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) | Not available           |
| 9.4 Trastuzumab Emtansine (Kadcyla)                                                         | Not available           |

3 July 2025

**Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of Jan 2025 to the end of Mar 2025, or latest 3-month period for which data are available?**

| Treatment intent                    | Number patients treated |
|-------------------------------------|-------------------------|
| 10.1 HER2+ <b>ve</b> Breast Cancer  | Not available           |
| 10.2 HER2- <b>low</b> Breast Cancer | Not available           |